Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin Plus Rituximab for CD30+/EBV+ Lymphomas
NCT01805037Phase 2Terminated
- Sponsor
- Northwestern University
- Start
- Mar 2013
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in lymphoma, sponsored by Northwestern University. Started Mar 2013; status: terminated.
02
Drugs
brentuximab vedotin
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT01805037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01805037.